New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
12:25 EDTBLUE, BLUE, BMRN, BMRN, CELG, CELG, CLDN, CLDN, MDGN, MDGN, QURE, QURE, SGMO, SGMO, AGTC, AGTC, ALGN, ALGNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Biopharmaceuticals Analyst Schimmer discusses gene therapy and highlights public and private companies involved in the field, as well as the large-cap pharma partnerships on an Analyst/Industry conference call. Relevant companies AGTC, ALGN, BLUE, BMRN, CELG, CLDN, MDGN, QURE and SGMO may be included on the Analyst/Industry conference call to be held on June 18 at 2 pm.
News For AGTC;ALGN;BLUE;BMRN;CELG;CLDN;MDGN;QURE;SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 19, 2015
08:57 EDTBLUEPiper sees upside to LentiGlobin launch expectations
Piper Jaffray sees upside potential to its expectation that LentiGlobin will launch in 2020 after the bluebird bio this morning provided a regulatory update. Piper believes approval in Europe for treatment of beta-thal major could come as much as three years earlier than expected while approval in the U.S. is likely to be ahead of expectations as well. The firm reiterates an Overweight rating on bluebird with a $186 price target.
08:21 EDTBLUEbluebird bio approval may come sooner than expected, says JPMorgan
JPMorgan analyst Cory Kasimov reiterates an Overweight rating on bluebird bio after the company announced this morning regulatory plans for LentiGlobin in B-thalassemia in the U.S. and Europe. Kasimov says approval could come earlier than the firm's current 2019 estimate with bluebird seeking accelerated approval in both geographies. The analyst recommends remaining a buyer of the stock ahead of the B-thalassemia data in June. Shares of the clinical-stage biotechnology company are up $5.60 to $162 in pre-market trading.
08:17 EDTCELGCelgene says patients experienced clinical remission in Phase II GED-0301 trial
Subscribe for More Information
06:05 EDTBLUEbluebird bio discusses potential approval pathways for LentiGlobin BB305
Subscribe for More Information
May 18, 2015
08:44 EDTCELGCelgene data positive, says SunTrust
SunTrust believes that data presented for Celgene's GED-0301 in Crohn's indicated that the drug is effective irrespective of baseline disease severity and CRP levels.Consequently, the firm thinks the data addressed questions raised in an NEJM editorial about the drug. It keeps a $141 price target and Buy rating on the shares.
07:31 EDTCELGCelgene, Acceleron granted fast track designations for luspatercept
Subscribe for More Information
07:06 EDTSGMOSangamo presents new data from proprietary ZFP therapeutic programs
Subscribe for More Information
May 15, 2015
09:11 EDTCLDNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Bsquare (BSQR), up 34.2%... Applied Materials (AMAT), up 3.2%. ALSO HIGHER: Trillium Therapeutics (TRIL), up 13% after being initiated with an Outperform at Oppenheimer... Pernix Therapeutics (PTX), up 7.4% after announcing FDA approval of Treximet for use in pediatric patients... Advaxis (ADXS), up 4.4% after being initiated with a Buy at Jefferies... Netflix (NFLX), up 3.3% following a Bloomberg report that the company is in talks to enter China's online video market... Inovalon (INOV), up 2.9% after being upgraded to Buy from Neutral at Goldman. DOWN AFTER EARNINGS: El Pollo LoCo (LOCO), down 12.8%... King Digital (KING), down 8.3%. ALSO LOWER: PlasmaTech (PTBI), down 5.4% after filing to sell 1.93M shares for selling stockholders... Paycom Software (PAYC), down 7% after 8M share Spot Secondary priced at $36.25... Keurig Green Mountain (GMCR), down 5.9% after Keurig Kold investor presentation... 3D Systems (DDD), down 2.4% after CFO transition... Celladon (CLDN), down 5.1% after the CEO says that the company is evaluating strategic options.
May 14, 2015
16:38 EDTCLDNCelladon CEO says evaluating strategic options
"We are in the process of conducting an extensive review of the CUPID2 data in the attempt to better understand the observed negative outcome. Meanwhile, we are conserving our cash resources and are assessing our other previously planned clinical trials and development programs. We are also evaluating our strategic options in order to determine the best path forward to maximize shareholder value," said Krisztina Zsebo, Ph.D., CEO of Celladon.
16:35 EDTCLDNCelladon reports Q1 net loss ($16.7M) vs.($7.2M) in 1Q14
Cash, cash equivalents and investments as of March 31 were $70.6M.
11:11 EDTCELGAnalysts divided on significance of Celgene blood cancer drug data
Subscribe for More Information
09:35 EDTBMRNBioMarin management to meet with Jefferies
Subscribe for More Information
09:11 EDTSGMOSangamo updates HIV and cancer candidates results
Sangamo BioSciences announced clinical and preclinical data from several ZFP Therapeutic programs and collaborations demonstrating new evidence of viral control in HIV/AIDS. Two trials of the company's ZFP Therapeutic, SB-728-T, which is being developed as a potential 'functional cure' for HIV/AIDS, demonstrated the effect of SB-728-T treatment on both viral load control and HIV reservoir reduction in HIV-infected subjects. Data were also presented demonstrating the successful incorporation of ZFN-mediated genome editing into an existing clinical scale production method to improve the anti-tumor activity of a tumor infiltrating lymphocyte-based therapeutic for melanoma.
May 13, 2015
17:42 EDTCELGCelgene announces over 55 blood, solid tumor cancer study presentations at ASCO
Subscribe for More Information
13:40 EDTBLUEbluebird bio June volatility elevated on wide price movement
Subscribe for More Information
May 12, 2015
07:33 EDTCELGAlliqua announces licensing agreement with Celgene
Subscribe for More Information
May 11, 2015
16:59 EDTAGTCApplied Genetic files to sell $125M shares of common stock
16:36 EDTAGTCApplied Genetic reports Q3 EPS (38c), consensus (33c)
Subscribe for More Information
14:34 EDTBLUEbluebird bio June volatility elevated on sharp rally
bluebird bio May call option implied volatility is at 73, June is at 109, August is at 82; compared to its 90-day average of 86, suggesting large near term price movement.
07:51 EDTBLUEConference should be positive turning point for bluebird bio, says SunTrust
SunTrust expects data due to be released at the EHA conference to create a positive turning point for bluebird bio. The firm notes that the data will include information on a sickle cell patient treated with bluebird's LentiGlobin, and the firm thinks that LentiGlobin is an effective sickle cell treatment. The firm now includes sickle cell in its estimates for the company and raised its price target on the shares to $205 from $115. It keeps a Buy rating o nthe stock.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use